Medtronic to acquire Scientia Vascular for $550M in neurovascular care

Medtronic announced it has entered into a definitive agreement to acquire Scientia Vascular. The acquisition is valued at $550 million, subject to customary adjustments, with potential undisclosed earn-out and milestone payments. Scientia Vascular is a private company operating in Salt Lake City, Utah, with approximately 310 employees. The company has developed access products including guidewires and catheters that can be integrated with Medtronic's neurovascular products. The acquisition is expected to close in the first half of FY27, subject to regulatory approvals and satisfaction of other closing conditions. It is expected to be minimally dilutive to Medtronic adjusted EPS in FY27 and accretive thereafter. Linnea Burman, senior vice president and president of Medtronic's Neurovascular business, said the acquisition positions Medtronic with a full suite of products supporting procedures across both hemorrhagic and acute ischemic stroke. Rick Randall, CEO of Scientia, said the deal allows the company to take its engineering into disease states globally and positions Medtronic with a comprehensive portfolio. Dr. David Fiorella, director of the Cerebrovascular Center at Stony Brook Medicine, said better microwires and microcatheters make every single case technically easier, faster, and safer for patients.